Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1891 to 1905 of 9085 results

  1. Edaravone for treating amyotrophic lateral sclerosis [TSID11869]

    Awaiting development Reference number: GID-TA11362 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Zavegepant for treating acute migraine [TSID11998]

    Awaiting development Reference number: GID-TA11527 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. School-based interventions: physical and mental health and wellbeing promotion

    In development Reference number: GID-QS10070 Expected publication date: TBC

    Quality standard
    In development

  4. Infant, children and young people's experience of health care

    Awaiting development Reference number: GID-QS10102 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Managing symptoms with an uncertain cause

    Awaiting development Reference number: GID-QS10103 Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Readmission to ICU within 48hrs

    Awaiting development Reference number: GID-QS10105 Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

    Awaiting development Reference number: GID-QS10106 Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Indoor air quality at home

    In development Reference number: GID-QS10113 Expected publication date: TBC

    Quality standard
    In development

  9. Children and young people with disabilities and severe complex needs: integrated health and social care support

    Awaiting development Reference number: GID-QS10146 Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Infection prevention and control update

    In development Reference number: GID-QS10177 Expected publication date: TBC

    Quality standard
    In development

  11. Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

    Awaiting development Reference number: GID-TA10638 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

    Awaiting development Reference number: GID-TA10700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Bupivacaine–meloxicam for treating postoperative pain [ID2728]

    Awaiting development Reference number: GID-TA10716 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [ID6664]

    Awaiting development Reference number: GID-TA11596 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [ID6694]

    Awaiting development Reference number: GID-TA11933 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development